March 1, 2011
I interviewed Bruce Brew, M.D., who spoke on neuropathogenesis at the Workshop for New Investigators and Trainees as the 18th Conference on Retroviruses and Opportunistic Infections opened in Boston, Mass., on Feb. 27. The video of the interview, which was produced by the International Foundation for Alternative Research in AIDS, is below (video by Jim Thompson):
In the interview, Brew recapped three key points that he made in his presentation:
Nadir CD4+ cell count might be important for people off, or prior to, treatment, Brew said. However, he acknowledged that the target level keeps shifting. Is it 200 cells/mm3? 350? 500? We don't know.
We discussed the issue of CNS penetration of antiretrovirals and its importance, which is still under debate. Some of the best-penetrating medications are also the most toxic to the brain, for example zidovudine (AZT, Retrovir). Evidence is slim, but accumulating, that better CNS penetration may lead to better clinical outcomes.
Brew mentioned the need to be aware of therapies in related fields, such as multiple sclerosis, and to be ready to apply any learnings where possible.
Finally, he said that after a period in which there was almost no interest in research into CNS issues -- it was assumed that potent antiretrovirals would eliminate the CNS problems -- there is now growing interest in this area of scientific exploration.
Copyright © 2011 The HealthCentral Network, Inc. All rights reserved.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|